Chen Iris H, Nicolau David P
Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.
Antibiotics (Basel). 2020 Jul 9;9(7):393. doi: 10.3390/antibiotics9070393.
Augmented renal clearance (ARC) refers to the state of heightened renal filtration commonly observed in the critically ill. Its prevalence in this patient population is a consequence of the body's natural response to serious disease, as well as the administration of fluids and pharmacologic therapies necessary to maintain sufficient blood pressure. ARC is objectively defined as a creatinine clearance of more than 130 mL/min/1.73 m and is thus a crucial condition to consider when administering antibiotics, many of which are cleared renally. Using conventional dosing regimens risks the possibility of subtherapeutic concentrations or clinical failure. Over the past decade, research has been conducted in patients with ARC who received a number of antibacterials frequently used in the critically ill, such as piperacillin-tazobactam or vancomycin. Strategies to contend with this condition have also been explored, though further investigations remain necessary.
肾脏清除率增加(ARC)是指在危重症患者中常见的肾脏滤过增强状态。在这一患者群体中的发生率是机体对严重疾病的自然反应以及为维持足够血压而进行的液体输注和药物治疗的结果。ARC的客观定义为肌酐清除率超过130 mL/min/1.73 m²,因此在使用许多经肾脏清除的抗生素时,这是一个需要考虑的关键情况。采用传统给药方案有导致治疗浓度不足或临床治疗失败的风险。在过去十年中,对接受危重症患者常用的多种抗菌药物(如哌拉西林-他唑巴坦或万古霉素)治疗的ARC患者进行了研究。应对这种情况的策略也已得到探索,不过仍需进一步研究。